Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University Greifswald, Germany.
Thromb Res. 2013 Mar;131(3):e85-90. doi: 10.1016/j.thromres.2013.01.005. Epub 2013 Jan 23.
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4/heparin (PF4/hep) complexes. The in vitro demonstration of PF4/hep antibodies using functional and immunological methods is essential for optimal management of patients suspected to have HIT. Since functional assays are technically challenging and limited to specialized laboratories, antigen-binding assays are commonly used in routine laboratories.
Blood samples from 448 consecutive patients in whom HIT was suspected were investigated using a latex agglutination test HemosIL® HIT-Ab(PF4-H) (HemosIL-Ab), two chemiluminescence tests HemosIL AcuStar HIT-Ab(PF4-H) (HemosIL AcuStar-Ab) and AcuStar HIT-IgG(PF4-H) (HemosIL AcuStar-IgG), an in-house PF4/hep IgG enzyme immunoassay (EIA) and the heparin induced platelet aggregation (HIPA) test.
Antibodies against PF4/hep were detectable in 44 out of 119 samples using HemosIL-Ab among which 20 samples were also reactive in the HIPA; and in 122, 64 and 108 out of 448 sera using HemosIL AcuStar-Ab, HemosIL AcuStar-IgG and in-house PF4/hep IgG-EIA, respectively, among which 52 sera were also reactive in the HIPA. All assays had high sensitivities of >95% for platelet activating antibodies; however, they differed in their specificities. The highest specificity and positive predictive value was observed by HemosIL AcuStar-IgG (96% and 78%, respectively).
Automated immunoassays are useful in the laboratory investigations of HIT and present a potential improvement toward standardization of laboratory investigations of HIT. The high positive predictive capability may justify treating the patient with alternative anticoagulants without waiting for the results of a functional assay.
肝素诱导的血小板减少症(HIT)是由识别血小板因子 4/肝素(PF4/肝素)复合物的血小板激活抗体引起的。使用功能和免疫方法体外证明 PF4/肝素抗体对于最佳管理疑似 HIT 的患者至关重要。由于功能检测具有技术挑战性且仅限于专门的实验室,因此抗原结合检测通常在常规实验室中使用。
对怀疑患有 HIT 的 448 例连续患者的血液样本进行了调查,使用乳胶凝集试验 HemosIL® HIT-Ab(PF4-H)(HemosIL-Ab)、两种化学发光试验 HemosIL AcuStar HIT-Ab(PF4-H)(HemosIL AcuStar-Ab)和 AcuStar HIT-IgG(PF4-H)(HemosIL AcuStar-IgG)、一种内部 PF4/肝素 IgG 酶免疫分析(EIA)和肝素诱导的血小板聚集(HIPA)试验。
使用 HemosIL-Ab 在 119 个样本中的 44 个样本中检测到针对 PF4/肝素的抗体,其中 20 个样本在 HIPA 中也有反应;在 448 个血清样本中,HemosIL AcuStar-Ab、HemosIL AcuStar-IgG 和内部 PF4/肝素 IgG-EIA 分别检测到 122、64 和 108 个样本,其中 52 个样本在 HIPA 中也有反应。所有检测方法对血小板激活抗体的灵敏度均>95%;然而,它们的特异性不同。HemosIL AcuStar-IgG 的特异性和阳性预测值最高(分别为 96%和 78%)。
自动化免疫测定法可用于 HIT 的实验室研究,为 HIT 的实验室研究标准化提供了潜在的改进。高阳性预测能力可能证明在等待功能检测结果之前,使用替代抗凝剂治疗患者是合理的。